Today, we announced an exclusive partnership with PATHOMIQ to apply their advanced AI technology platform to our suite of oncology products ... The Ambry acquisition by Tempus just occurred ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ ... as "one of the largest libraries of clinical and molecular oncology data in the world." Many potential investors, however, are ...

More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, ...

Tempus is committed to helping physicians and researchers advance efforts in oncology, cardiology, pathology and radiology. "We are pleased to upsize our investment in Tempus, underscoring Ares ...

reflecting its growth potential in the precision oncology space. Further, TEM stock’s solid performance points to investors’ confidence in Tempus AI’s ability to use its AI technology for ...

In 2022 and 2023, Tempus AI reported year-over-year growth in its oncology NGS tests delivered of 53% and 48%, respectively. Should the company report a further decline in 2024 and the subsequent ...

This collaboration not only expands Tempus AI's data assets in a critical area of oncology but also validates its platform and analytical capabilities in the eyes of established research institutions.

Tempus AI has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Insider Activity ...

Tempus AI, Inc. Class A (TEM – Research Report) received a Hold rating and price target from William Blair analyst Andrew Brackmann today. The company’s shares closed yesterday at $89.44 ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom ...